anwerina Deutschland

Company snapshot

Wir sind ein junges hochspezialisiertes pharmazeutisches Unternehmen mit Sitz in Mannheim. Unsere Expertise im Bereich Knochengesundheit reicht zurück bis in das Jahr 1993 und gründet auf der Erfahrung des Procter & Gamble Pharma Teams als Erfinder der Bisphosphonate. „passion for patients“ - Unsere Leidenschaft für eine verbesserte Lebensqualität und optimale medizinische Versorgung für Patienten

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for anwerina Deutschland. Not investment advice.

• What is anwerina Deutschland?

  Warner Chilcott Deutschland is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypoactive Sexual Desire Disorder. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clinical

• Is anwerina Deutschland publicly traded?

  anwerina Deutschland appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does anwerina Deutschland develop or market?

  We link 1 drug profile(s) where anwerina Deutschland is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/warner-chilcott-deutschland-gmbh#company-drugs.

• What are the latest developments for anwerina Deutschland?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does anwerina Deutschland focus on?

  anwerina Deutschland focuses on Hypoactive Sexual Desire Disorder based on our analysis of their pipeline programs and drug development activities.